Drug-killing rates on leuprorelin-sensitive PSA-producing cancer cells were higher in subjects with higher baseline PSA levels and those with antiandrogen use within the 30 days of leuprorelin treatment initiation, compared to those with lower baseline PSA levels and those without antiandrogen use. The gene discussed is KLK3; the disease is cancer.